Averi Kit
NDC 75854-604

The NDC code 75854-604 is assigned by the FDA to the product Averi. It is commonly known by its generic name, desogestrel and ethinyl estradiol. This pharmaceutical product is labeled by Avion Pharmaceuticals, Llc and is currently categorized as listed product. The medication is a kit. In terms of distribution, this product is available in 2 different package configurations. The associated package NDC(s) include: 75854-604-01, 75854-604-03. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

AVERI is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.In a clinical trial with desogestrel and ethinyl estradiol tablets 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. This represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. This rate includes patients who did not take the drug correctly.Table 1: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES.  % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year3  Method(1)Typical Use1(2)Perfect Use2(3)(4) Chance4  85 85  Spermicides5  26 6 40 Periodic abstinence  25  63  Calendar  9   Ovulation Method  3   Sympto-Thermal6  2   Post-Ovulation  1  Withdrawal  19 4  Cap7      Parous Women 40 26 42  Nulliparous Women 20 9 56 Sponge      Parous Women 40 20 42  Nulliparous Women 20 9 56 Diaphragm7  20 6 56 Condom8      Female (Reality®) 21 5 56  Male 14 3 61 Pill  5  71  Progestin Only  0.5   Combined  0.1  IUD      Progesterone T 2.0 1.5 81  Copper T380A 0.8 0.6 78  LNg 20 0.1 0.1 81 Depo-Provera  0.3 0.3 70 Norplant® and Norplant-2®  0.05 0.05 88 Female Sterilization  0.5 0.5 100 Male Sterilization  0.15 0.10 100Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%.9Lactation Amenorrhea Method: LAM is a highly effective, temporary method of contraception.10Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998.1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.2Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.4 The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.5 Foams, creams, gels, vaginal suppositories, and vaginal film.6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.7With spermicidal cream or jelly.8 Without spermicides.9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The FDA has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 yellow pills).10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age.AVERI has not been studied for and is not indicated for use in emergency contraception.

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

• RxCUI: 240707 - desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet
• RxCUI: 2672922 - ferrous bisglycinate 36.5 MG Oral Tablet
• RxCUI: 2716396 - {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (ferrous bisglycinate 36.5 MG Oral Tablet) } Pack
• RxCUI: 2716396 - desogest-eth estra 0.15-0.03 MG (21) Oral Tablet / ferrous bisglycinate 36.5 MG (7) Oral Tablet 28 Day Pack
• RxCUI: 2716396 - {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (ferrous bisglycinate 36.5 MG Oral Tablet) } 28 Day Pack